Surgery in ovarian cancer

The role of surgery in the management of primary and recurrent ovarian cancer is reviewed. The data to support primary and secondary cytoreduction are summarized. The role of second-look surgery and of surgery in the palliation of ovarian cancer is also discussed.

Primary cytoreduction; Neoadjuvant chemotherapy; Secondary cytoreduction; Second-look laparotomy

[1] Heintz A. P., Hacker N. F., Berek J. S. et al.: "Cytoreductive surgery in ovarian carcinoma: feasibility and morbibity". Obstet. Gynecol., 1986, 67, 783.

[2] Eisenkop S. M., Friedman R. L., Wang H.J.: "Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study". Gynecol. Oneal., 1998, 69, 103.

[3] Hoskins W. J.: "Epithelial ovarian carcinoma: principles of primary surgery". Gynecol. Oneal., 1994, 55, S91.

[4] Hoskins W. J., McGuire W. P., Brady M. F. et al.: "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.

[5] Hoskins W. J., Bundy B. N., Thigpen J. T. et al.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study". Gynecol. Oneal., 1992, 47, 159.

[6] Nguyen H. N., Averette H. E., Hoskins W. et al.: "National survey of ovarian carcinoma. Part V. The impact of physician's specialty on patients'survival". Cancer, 1993, 72, 3663.

[7] Averette H. E., Hoskins W., Nguyen H. N. et al.: "National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons". Cancer, 1993, 71 (Suppl)., 1629.

[8] Munoz K. A., Harlan L. C., Trimble E. L.: "Patterns of care for women with ovarian cancer in the United States". J. Clin. Oneal., 1997, 15, 3408.

[9] Webb M. J.: "Cytoreduction in ovarian cancer: achievability and results". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 83.

[10] Benedetti-Panici P., Maneschi F., Scambia G. et al.: "The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma". Obstet. Gynecol., 1996, 87, 532.

[11] Scarabelli C.,G allo A., Franceschi S. et al.: "Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma". Cancer, 2000, 88, 389.

[12] Tamussino K. F., Lim P. C., Webb M. J. et al.: "Gastrointestinal surgery in patients with ovarian cancer". Gynecol. Oncol., 2001, 80, 79.

[13] Weber A. M., Kennedy A. W.:'The role of bowel resection in the primary surgical debulking of carcinoma of the ovary". J. Am Coll. Surg., 1994, 179,465.

[14] Bristow R. E., Montz F. J., Lagasse L. D. et al.: "Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer". Gynecol. Oncol., 1999, 72, 278.

[15] Merideth M.A., Nagorney D. M., Lesnick T. et al.: " Hepatic resection for metachronous metastases from ovarian carcinoma(abstract)". Gynecol. Oncol., 2000, 76, 280.

[16] Adelson M. D.: " U ltrasonic surgical aspirator in cytoreduction of splenic metastases to avoid splenectomy". J. Reprod. Med., 1992, 37,917.

[17] Chen L. M., Leuchter R. S., Lagasse L. D. et al.: "Splenectomy and surgical cytoreduction for ovarian cancer". Gynecol. Oncol., 2000, 77, 362.

[18] Scarabelli C.,G allo A., Zarrelli A. et al.: "Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival". Gynecol. Oncol., 1995, 56, 328.

[19] di Re F., Baiocchi G., Fontanelli R. et al.: "Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases". Gynecol. Oncol., 1996, 62, 360.

[20] Boente M. P., Chi D.S., Hoskins W. J.:'The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery". Semin. Oncol., 1998, 25, 326.

[21] Ng L. W.,R ubin S. C., Hoskins W.J . et al.: "Aggressive chemosurgical debulking in patients with advanced ovarian cancer" Gynecol. Oncol., 1990, 38, 358.

[22] Schwartz P.E .,R utherford T. J.,C hambers J. T. et al.: "Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival". Gynecol. Oncol., 1999, 72, 93.

[23] ChambersJ . T.,C hambers S. K.,Vo ynick I. M. et al.: "Neoadjuvant chemotherapy in stage X ovarian carcinoma". Gynecol. Oncol., 1990, 37, 327.

[24] van der Burg M. E., van Lent M., Buyse M. et al.: "The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer". N. Engl. J. Med., 1995, 332, 629.

[25] Williams L.: "The role of secondary cytoreductive surgery in epithelial ovarian malignancies". Oncology (Hunting ed.) 1992, 6:25.

[26] Hem piing R.E .,W esolowski J. A.,P iver M.S .: "Second-look laparotomy in advanced ovarian cancer: a critical assessment of morbibity and impact on survival". Ann. Surg. Oncol., 1997, 4, 349.

[27] Podratz K. C.,S chray M. F., Wieand H. S. et al.: "Evaluation of treatment and survival after positive second-look laparotomy" Gynecol. Oncol., 1988, 31, 9.

[28] Free K. E., Webb M. J.: "Second-look laparotomy-clinical correlations". Gynecol. Oncol., 1987, 26, 290.

[29] Rubin S. C.,R andall T. C.,A rmstrong K.A . et al.: "Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings". Obstet. Gynecol., 1999, 93, 21.

[30] Podratz K. C.,M alkasian G. D.J r.,W ieand H.S . et al.: "Recurrent disease after negative second-look laparotomy in stages III and IV ovarian carcinoma". Gynecol. Oncol., 1988, 29, 274.

[31] Hoskins W. J.,R ubin S. C.,D ulaney E. et al.: " Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma". Gynecol. Oncol., 1989, 34, 365.

[32] Williams L., Brunetto V. L., Yordan E. et al.: "Secondary cytoreductive surgery at second-look laparotomy in advanced ovanan cancer: a Gynecologic Oncology Group Study". Gynecol. Oncol., 1997, 66, 171.

[33] Baiocchi G.,G rosso G.,d i Re E. et al.: "Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer". Gynecol. Oncol., 1998, 69, 151.

[34] Burke T. W., Moms M.: "Secondary cytoreductive surgery for ovarian cancer". Obstet. Gynecol. Clin. North. Am., 1994, 21, 167.

[35] Segna R. A., Dottino P.R., Mandeli J.P. et al.: "Secondary cytoreduction for ovarian cancer following cisplatin therapy". J. Clin Oncol., 1993, 11, 434.

[36] Gemignani M. L.,C hi D.S.,G urin C. C. et al.: "Splenectomy in recurrent epithelial ovarian cancer". Gynecol. Oncol., 1999, 72, 407.

[37] Michel G., Zarca D., Castaigne D. et al.: "Secondary cytoreductive surgery in ovarian cancer". Eur. J. Surg. Oncol., 1989, 15, 201.

[38] Morris M.,G ershenson D. M., Wharton J. T. et al.: "Secondary cytoreductive surgery for recurrent epithelial ovarian cancer". Gynecol. Oncol., 1989, 34, 334.

[39] Berek J. S., Hacker N. F., Lagasse L. D. et al.: "Survival of patients following secondary cytoreductive surgery in ovarian cancer" Obstet. Gynecol., 1983, 61, 189.

[40] Kuhn W.,S chmalfeldt B.,P ache L. et al.: " Disease-adapted relapse therapy for ovarian cancer: results of a prospective study". Int. J. Oncol., 1998, 13, 57.

[41] Eisenkop S. M., Friedman R. L., Wang H.J.: "Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study" Cancer, 1995, 76, 1606.

[42] Eisenkop S. M., Friedman R. L.,S pirtos N. M.: "The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma". Cancer, 2000, 88, 144.